| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Lexicon Pharmaceuticals, Inc. (LXRX) has 9 insiders with recent SEC Form 4 filings, including 40 buys and 1 sell. LXRX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.91M | $3.92M | - | |
| CEO | 1.01M | $2.07M | - | |
| CFO | 160.2K | $329.3K | - | |
| VP | 156.0K | $320.7K | - | |
| VP | 149.3K | $306.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 4, 2018 | Invus Public Equities, L.P.78 | Director, 10% Owner | Buy | 416,481 | $12.01 | $5,002,666.67 | +6.5% | |
| May 30, 2018 | Invus Public Equities, L.P.78 | Director, 10% Owner | Buy | 433,378 | $9.94 | $4,306,418.18 | +8.5% | |
| May 23, 2018 | Santini Alexander A | EVP And CCO | Buy | 745 | $9.78 | $7,286.10 | +16.4% | |
| Nov 17, 2017 | Invus Public Equities, L.P.78 | Director, 10% Owner | Buy | 180,727 | $10.11 | $1,826,895.85 | +6.3% | |
| Nov 15, 2017 | Coats Lonnel | President And CEO | Buy | 10,000 | $9.91 | $99,100.00 | +30.3% | |
| Nov 14, 2017 | Wade Jeffrey L | EVP, Corp Adm Affairs And CFO | Buy | 2,000 | $9.48 | $18,961.80 | +4.1% | |
| Nov 14, 2017 | Invus Public Equities, L.P.78 | Director, 10% Owner | Buy | 575,946 | $9.64 | $5,554,165.52 | +20.0% | |
| Sep 15, 2017 | Coats Lonnel | President And CEO | Buy | 30,000 | $12.54 | $376,336.70 | +5.2% | |
| Sep 15, 2017 | Barker Sam L | Director | Buy | 1,000 | $12.50 | $12,500.00 | +4.1% | |
| Jun 6, 2016 | Tessmer James F | VP, Finance &Accounting | Sale+OE | 1,500 | $15.00 | $22,500.00 | -8.6% |